AllTRNA is a leading online platform that provides comprehensive information and resources about transfer RNA (tRNA). It offers a wide range of educational content, research articles, and tools to help scientists, researchers, and students understand the role and functions of tRNA in protein synthesis.

Noubar Afeyan

Lovisa Afzelius

Theonie Anastassiadis

AllTRNA

Alltrna is the first transfer RNA (tRNA) platform company, and our mission is to unlock tRNA biology and pioneer tRNA therapeutics to regulate the protein universe and resolve disease. Founded at Flagship Labs in 2018, Alltrna has mapped tRNA biology to systematically design tRNA medicines and encode a completely new, unifying approach to treating both rare and common human diseases driven by shared genetic mutations. Alltrna’s platform combines internal expertise and proprietary machine learning tools to unlock the entire tRNA biology space. We have an unprecedented opportunity to advance a single tRNA medicine to restore disrupted protein production, regardless of target, for thousands of diseases with the same underlying genetic mutation.

Flagship Pioneering

Alltrna

We’re thrilled to announce our Series B financing of $109 million with a world-class group of investors. This financing will support further scaling of our platform and advancing our first #tRNA medicines to clinical trials as we build a new future for patients with #StopCodonDisease.

Read the release here: https://lnkd.in/gJcC65nx

#financing #biotech #Boston

Our CEO Michelle Werner spoke with Ray Dogum at Vibe Bio about the unique ability of #tRNA medicines to potentially treat thousands of #rarediseases which share the same genetic mutations.

Learn more about #StopCodonDisease and #tRNA biology on this #VibeCast episode: https://lnkd.in/gYTrxRuh

At Alltrna, health and well-being is something we prioritize for our employees. We took a synchronous #summerbreak the first week of July, knowing that this time away fosters creativity and rejuvenation. Check out the video showcasing the fun experiences of our team during their time off. We know that our commitment to patients is best fulfilled when we take care of ourselves as well.

#EmployeeWellness #WorkLifeBalance #Innovation #WeAreAlltrna

For #DisabilityPrideMonth, our CEO Michelle Werner writes about how helping her son, who has #Duchenne #musculardystrophy, navigate the world made it clear why accessibility is necessary to creating inclusive and diverse cultures. #AlltrnaForAll #culture #diversityandinclusion #workplacediversity #accessibility

We are excited to share this quarter’s #EmployeeSpotlight featuring Derrick Allen, one of our senior scientists. Derrick’s specialty lies in analysis, which he likens to figuring out a puzzle. At Alltrna, he has helped build the CMC lab and team from scratch and is motivated daily by the drive to ensure quality in our data to drive better patient outcomes.

If you are interested in building a bold new future for patients, check out our #openpositions: https://lnkd.in/ghQQGi3s

#wearehiring #joinus #tRNA #tRNAbiology #tRNAmedicines #tRNAtherapeutics #programmablemedicines

For our first day of service, our team members volunteered at Cradles to Crayons Massachusetts and Community Servings. It was rewarding giving back to our community and supporting those in need. At Alltrna, our values guide us every step of the way. We give it our all, every day – in and outside the office! #WeAreAlltrna

For our first day of service, our team members volunteered at Cradles to Crayons Massachusetts and Community Servings. It was rewarding giving back to our community and supporting those in need. At Alltrna, our values guide us every step of the way. We give it our all, every day – in and outside the office! #WeAreAlltrna.

This week our CEO, Michelle Werner, contributed to an impactful #BIO2023 panel discussing leadership advantages women bring to the C-suite. The panel's key takeaway: women possess not just soft skills like empathy and inclusion, but they unequivocally deliver results and act as catalysts. Michelle is definitely a catalyst, and we are proud to have her leading Alltrna!

#WomenInLeadership #WomenInBiopharma

Next week our CEO Michelle Werner will be in-person at the #LongwoodHealthcareLeaders conference discussing accelerating the path to patient care on a panel with execs from Moderna, Akili Labs, Karyopharm Therapeutics Inc., and Galera Therapeutics, Inc.  

See the full agenda for Longwood Healthcare Leaders Spring MIT Conference: https://lnkd.in/e4AhEbXp

#tRNA #rarediseases #cancer #tRNAmedicines #tRNAtherapeutics

We are delighted to share that our CEO Michelle Werner will be joining other high-profile female #BioPharmaLeaders for a candid discussion on how to lead the industry through the bear market with high-risk decision making, emotionally intelligent leadership, resilience, and collaboration. 

More info: https://lnkd.in/gkRkgKjE

#WomenInLeadership #BIO2023 #BiopharmaLeadership #Innovation #WomenInSTEM

Metric
Company Name	AllTRNA
Symbol
MSH ID	COM:ALLTRNA
Market	PRIVATE
Sector	Life Sciences
Industry	Biotechnology
Country	US
Stage	Series B
Employee Count	68
Website	alltrna.com
LinkedIn	alltrna
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic	3.35K
Web Traffic Growth	1.45
Valuation
Raised Capital	109M

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:ALLTRNA

AllTRNA

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue